Company profile: Advesya
1.1 - Company Overview
Company description
- Provider of therapies for difficult-to-treat cancers, focusing on immuno-oncology and hematological malignancies, leveraging biochemistry and molecular and cellular biology expertise. Offers ADV-101, a topoisomerase I inhibitor antibody-drug conjugate targeting IL-1RAP for esophageal cancer, delivering cytotoxic agents directly to cancer cells.
Products and services
- Immuno-Oncology Therapy Development: Engineers research-grade programs that develop therapies for difficult-to-treat cancers, leveraging biochemistry plus molecular and cellular biology expertise to improve patient outcomes within immuno-oncology
- Hematological Malignancy Therapy Development: Architects molecular biology–driven programs targeting hematological malignancies, applying biochemistry and cellular biology expertise to produce innovative cancer therapies focused on challenging hematological malignancies
- ADV-101: Custom-engineered topoisomerase I inhibitor antibody-drug conjugate targeting IL-1RAP, designed to treat esophageal cancer by delivering cytotoxic agents directly to malignant cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Advesya
Scandinavian ChemoTech
HQ: Sweden
Website
- Description: Provider of cancer care technologies, including IQwave – TSE (Tumour Specific Electroporation), a device and method that enhances uptake of cytotoxic drugs into tumor cells via electroporation, and D-EECT (Dynamic‑ElectroEnhanced ChemoTherapy), a treatment protocol aimed at better clinical outcomes for palliative patients with large tumor burdens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scandinavian ChemoTech company profile →
Molecular Insight
HQ: United States
Website
- Description: Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Insight company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
Onco-NX
HQ: United Kingdom
Website
- Description: Provider of drug discovery research dedicated to identifying new promising anticancer agents as a University of Salford spin-out company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onco-NX company profile →
GT MedTech
HQ: United States
Website
- Description: Provider of surgically targeted radiation therapy for operable brain tumors via GammaTile Therapy, delivering immediate, dose-intense treatment post-resection to extend local recurrence-free survival; conducts clinical trials evaluating GammaTile for newly diagnosed metastatic brain tumors and recurrent glioblastoma; and offers a digital Brain Resection Cavity Estimation Tool to aid tumor bed calculations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GT MedTech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Advesya
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Advesya
2.2 - Growth funds investing in similar companies to Advesya
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Advesya
4.2 - Public trading comparable groups for Advesya
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →